AstraZeneca Has Stake In Three Of Nine NCATS Research Projects
This article was originally published in The Pink Sheet Daily
Executive Summary
Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.
You may also be interested in...
Cipla Chief Calls For Invigorating Focus On Repurposed Drugs
Cipla chairman underscores the potential and value of repurposing drugs for Indian researchers and pharma firms looking to build their R&D activities, amid signs of growing attention to the promising area globally.
Pfizer CTI Research Network Expands With NIH Collaboration
The partnership, announced Dec. 4, marks the first time a U.S. government agency has entered into a collaborative arrangement to conduct research through Pfizer’s Centers for Therapeutic Innovation network.
NIH Drug Repurposing Program Produces Surprise Overlaps
Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.